"Developing new cancer therapies and molecular diagnostics requires extracting all relevant biological information from clinical samples that are often too small to characterize using multiple different assays, such as small biopsies from recurrent tumors," said
This initial immuno-oncology focused RNA:
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the scientific and medical potential of our technology to simultaneously profile gene and protein expression, and its ability to enhance the development of new cancer therapeutics in the field of immuno-oncology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for
diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
CONTACT: NanoString Contact:
Leigh Salvoof Westwicke Partnersleigh.firstname.lastname@example.org 415-513-1281
News Provided by Acquire Media